These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2013000)

  • 1. Moving ahead in cancer research: who pays for patient supportive care for participation in experimental/investigational trials?
    Monaco GP
    Cancer Invest; 1991; 9(1):85-92. PubMed ID: 2013000
    [No Abstract]   [Full Text] [Related]  

  • 2. Reimbursing new technologies: why are the courts judging experimental medicine?
    Saver RS
    Stanford Law Rev; 1992 May; 44(5):1095-131. PubMed ID: 10119850
    [No Abstract]   [Full Text] [Related]  

  • 3. Paying for patient care in treatment research--who is responsible?
    Wittes RE
    Cancer Treat Rep; 1987 Feb; 71(2):107-13. PubMed ID: 3100033
    [No Abstract]   [Full Text] [Related]  

  • 4. Criteria for standard versus experimental therapy.
    Reiser SJ
    Health Aff (Millwood); 1994; 13(3):127-36. PubMed ID: 7927143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical insurance payments and patients involved in research.
    Holder AR
    IRB; 1994; 16(1-2):19-22. PubMed ID: 11652323
    [No Abstract]   [Full Text] [Related]  

  • 6. Group of insurers to pay for experimental cancer therapy.
    Kolata G; Eichenwald K
    N Y Times Web; 1999 Dec; ():C1, C10. PubMed ID: 11647711
    [No Abstract]   [Full Text] [Related]  

  • 7. Who should rightfully decide whether a medical treatment necessarily incurred should be excluded from coverage under a health insurance policy provision which excludes from coverage "experimental" medical treatments?
    Fisfis BA
    Duquesne Law Rev; 1993; 31(4):777-800. PubMed ID: 11652669
    [No Abstract]   [Full Text] [Related]  

  • 8. What's the price of a research subject? Approaches to payment for research participation.
    Dickert N; Grady C
    N Engl J Med; 1999 Jul; 341(3):198-203. PubMed ID: 10403861
    [No Abstract]   [Full Text] [Related]  

  • 9. Undefined experimental treatment exclusions in health insurance contracts: a proposal for judicial response.
    Belk J
    Wash Law Rev; 1991 Jul; 66(3):809-30. PubMed ID: 11652624
    [No Abstract]   [Full Text] [Related]  

  • 10. Who's paying for new drugs?
    Oldham RK
    Nature; 1988 Apr; 332(6167):795. PubMed ID: 3282177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Funding innovative medical treatment.
    Holder AR
    Albany Law Rev; 1994; 57(3):795-810. PubMed ID: 11652865
    [No Abstract]   [Full Text] [Related]  

  • 12. Subjects would have more freedom to pick experimental treatments.
    Mahoney DM
    Hum Res Rep; 2000 Apr; 15(4):9. PubMed ID: 11658148
    [No Abstract]   [Full Text] [Related]  

  • 13. Reimbursement issues facing patients, providers, and payers.
    Antman K
    Cancer; 1993 Nov; 72(9 Suppl):2842-5. PubMed ID: 8402516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational treatments: coverage, controversy, and consensus.
    Ader M
    Ann Health Law; 1996; (5):45-60. PubMed ID: 10164521
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of clinical trial protocols on patient care systems at the University of Texas M.D. Anderson Cancer Center.
    Huber SL
    Cancer; 1993 Nov; 72(9 Suppl):2824-7. PubMed ID: 8402512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Funding clinical trials: who will pay?
    Glaser RJ
    Pharos Alpha Omega Alpha Honor Med Soc; 1994; 57(2):44. PubMed ID: 8022876
    [No Abstract]   [Full Text] [Related]  

  • 17. Barriers to clinical trial enrollment: are state mandates the solution?
    Hillner BE
    J Natl Cancer Inst; 2004 Jul; 96(14):1048-9. PubMed ID: 15265958
    [No Abstract]   [Full Text] [Related]  

  • 18. The crisis in clinical cancer research. Third-party insurance and investigational therapy.
    Antman K; Schnipper LE; Frei E
    N Engl J Med; 1988 Jul; 319(1):46-8. PubMed ID: 3288868
    [No Abstract]   [Full Text] [Related]  

  • 19. Emerging technologies and medical coverage.
    Merrikin K; Smith S
    Clin Ethics Rep; 1996; 10(1):9-12. PubMed ID: 11660222
    [No Abstract]   [Full Text] [Related]  

  • 20. Access to cancer care and clinical trials: a time for reappraisal.
    Runowicz CD; Berman ML
    Womens Health Issues; 1996; 6(2):112-3. PubMed ID: 8932466
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.